Table 1 Most common treatment-related adverse events (trAEs)
Specific AEs | Any grade | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|---|---|---|---|---|---|
Diarrhea | 15 (75.0%) | 5 (25.0%) | 9 (45.0%) | 1 (5.0%) | 0 (0.0%) |
Hyperglycemia | 11 (55.0%) | 11 (55.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Asthenia | 8 (40.0%) | 4 (20.0%) | 4 (20.0%) | 0 (0.0%) | 0 (0.0%) |
Hypercholesterolemia | 8 (40.0%) | 8 (40.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Hypomagnesaemia | 7 (35.0%) | 6 (30.0%) | 1 (5.0%) | 0 (0.0%) | 0 (0.0%) |
Abdominal pain | 5 (25.0%) | 2 (10.0%) | 2 (10.0%) | 1 (5.0%) | 0 (0.0%) |
Anorexia | 5 (25.0%) | 4 (20.0%) | 1 (5.0%) | 0 (0.0%) | 0 (0.0%) |
Creatinine increase | 4 (20.0%) | 4 (20.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Nausea | 4 (20.0%) | 3 (15.0%) | 1 (5.0%) | 0 (0.0%) | 0 (0.0%) |
Emesis | 4 (20.0%) | 3 (15.0%) | 1 (5.0%) | 0 (0.0%) | 0 (0.0%) |
Hypertriglyceridemia | 4 (20.0%) | 3 (15.0%) | 1 (5.0%) | 0 (0.0%) | 0 (0.0%) |
Hyperuricemia | 3 (15.0%) | 3 (15.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Hyponatremia | 2 (10.0%) | 2 (10.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Steatorrhea | 2 (10.0%) | 0 (0.0%) | 2 (10.0%) | 0 (0.0%) | 0 (0.0%) |
Intestinal bloating | 2 (10.0%) | 2 (10.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
GGT elevation | 2 (10.0%) | 1 (5.0%) | 1 (5.0%) | 0 (0.0%) | 0 (0.0%) |
Dysgeusia | 1 (5.0%) | 1 (5.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Hypokalemia | 1 (5.0%) | 0 (0.0%) | 1 (5.0%) | 0 (0.0%) | 0 (0.0%) |
Hypophosphatemia | 1 (5.0%) | 1 (5.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Decreased appetite | 1 (5.0%) | 1 (5.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Acute renal failure | 1 (5.0%) | 0 (0.0%) | 0 (0.0%) | 1 (5.0%) | 0 (0.0%) |